BMS Korea, AstraZeneca Korea expand diabetes alliance

Published: 2013-04-03 06:58:00

Updated: 2013-04-03 06:58:00

BMS Korea and AstraZeneca Korea received the Korean marketing rights of Byetta (exenatide) injection and Bydureon (exenatide extended-release for injectable suspension) from Lilly Korea as of April 1, following the successful completion of the acquisition of Amylin Pharmaceuticals by Bristol-Myers Squibb in August last year.

“The expansion of our diabetes alliance with AstraZeneca will incre...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.